The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells

Blood Cancer Journal

Volumn 1, Issue 5, 2011, Pages

  Kuwatsuka, Y ^a   Minami, M ^a   Minami, Y ^a   Sugimoto, K ^a   Hayakawa, F ^a   Miyata, Y ^a   Abe, A ^a   Goff, D J ^b   Kiyoi, H ^c   Naoe, T ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Everolimus; Imatinib resistance; MTOR inhibitor; Ph + ALL

Indexed keywords

BCR ABL PROTEIN; CRK LIKE PROTEIN; EVEROLIMUS; IMATINIB; PROTEIN MCL 1;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CD34 SELECTION; CELL CYCLE G0 PHASE; CELL DEATH; CELL POPULATION; CELL SELECTION; DRUG EFFECT; IN VIVO STUDY; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; MALE; MOUSE; NONHUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SCID MOUSE; SPLEEN CELL; TUMOR XENOGRAFT;

EID: 84864064318     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.16     Document Type: Article

References (38)

1. Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006; 108: 1469-1477. (Pubitemid 44316110)
2. Quintas-Cardama A, Kantarjian H, Cortes J. Imatinib and beyondFexploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009; 6: 535-543.
3. Jordan CT. The leukemic stem cell. Best Pract Res Clin Haematol 2007; 20: 13-18.
4. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267-1270. (Pubitemid 40943094)
5. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006; 12: 1181-1184. (Pubitemid 44527354)
6. O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 2006; 16: 92-99. (Pubitemid 43089618)
7. Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 2004; 101: 3130-3135. (Pubitemid 38327746)
8. Krause DS, Van Etten RA. Right on target: eradicating leukemic stem cells. Trends Mol Med 2007; 13: 470-481. (Pubitemid 350086980)
9. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441: 475-482. (Pubitemid 44050144)
10. Xu Q, Thompson JE, Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 2005; 106: 4261-4268. (Pubitemid 41775935)
11. Cullion K, Draheim KM, Hermance N, Tammam J, Sharma VM, Ware C et al. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood 2009; 113: 6172-6181.
12. Crazzolara R, Cisterne A, Thien M, Hewson J, Baraz R, Bradstock KF et al. Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 2009; 113: 3297-3306.
13. Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12: 5165-5173. (Pubitemid 44453345)
14. Chapuis N, Tamburini J, Green AS, Willems L, Bardet V, Park S et al. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia 2010; 24: 1686-1699.
15. Tanizaki R, Nomura Y, Miyata Y, Minami Y, Abe A, Hanamura A et al. Irrespective of CD34 expression, lineage-committed cell fraction reconstitutes and re-establishes transformed Philadelphia chromosome-positive leukemia in NOD/SCID/IL-2Rgammac-/- mice. Cancer Sci 2010; 101: 631-638.
16. Minami Y, Stuart SA, Ikawa T, Jiang Y, Banno A, Hunton IC et al. BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci USA 2008; 105: 17967-17972.
17. Minami Y, Yamamoto K, Kiyoi H, Ueda R, Saito H, Naoe T. Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia. Blood 2003; 102: 2969-2975. (Pubitemid 37248872)
18. Minami Y, Kiyoi H, Yamamoto Y, Yamamoto K, Ueda R, Saito H et al. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia 2002; 16: 1535-1540.
19. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999; 94: 2056-2064. (Pubitemid 29430422)
20. Ninomiya M, Abe A, Katsumi A, Xu J, Ito M, Arai F et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. Leukemia 2007; 21: 136-142. (Pubitemid 44921844)
21. Zhou Y, Pan Y, Zhang S, Shi X, Ning T, Ke Y. Increased phosphorylation of p70 S6 kinase is associated with HPV16 infection in cervical cancer and esophageal cancer. Br J Cancer 2007; 97: 218-222. (Pubitemid 47057468)
22. Abe A, Kiyoi H, Ninomiya M, Yamazaki T, Murase T, Ozeki K et al. Establishment of a stroma-dependent human acute myelomonocytic leukemia cell line, NAMO-2, with FLT3 tandem duplication. Int J Hematol 2006; 84: 328-336. (Pubitemid 46606574)
23. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25: 1315-1321. (Pubitemid 350076512)
24. Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Basecke J, Libra M et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 2009; 23: 25-42.
25. Holtz MS, Forman SJ, Bhatia R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 2005; 19: 1034-1041. (Pubitemid 40862017)
26. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737. (Pubitemid 27298715)
27. Cox CV, Diamanti P, Evely RS, Kearns PR, Blair A. Expression of CD133 on leukemia-initiating cells in childhood ALL. Blood 2009; 113: 3287-3296.
28. Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 2008; 319: 336-339.
29. Kong Y, Yoshida S, Saito Y, Doi T, Nagatoshi Y, Fukata M et al. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia 2008; 22: 1207-1213. (Pubitemid 351833789)
30. Campbell CJ, Lee JB, Levadoux-Martin M, Wynder T, Xenocostas A, Leber B et al. The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. Blood 2010; 116: 1433-1442.
31. Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ et al. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 2008; 105: 10853-10858.
32. Codogno P, Meijer AJ. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ 2005; 12(Suppl 2): 1509-1518. (Pubitemid 41553987)
33. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119: 1109-1123.
34. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484. (Pubitemid 43199434)
35. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101. (Pubitemid 40262113)
36. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27: 2278-2287.
37. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010; 16: 205-213.
38. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401-412.